Ontario is the eighth Canadian jurisdiction to switch patients with Crohn's disease and other conditions from life-changing biologic drugs to more cost-effective 'biosimilars.' Both options are considered effective, and the swap saves millions. But should patients be forced to make the change?
Post a Comment
EmoticonClick to see the code!
To insert emoticon you must added at least one space before the code.